In spite of the global recession, there are 7 persons in the Korean pharmaceutical industry, whose estimated value of stock has increased respectively more than 10 billion won for the first quarter of this year.

Among them, Lim Sung-Ki(Hanmi'Pharm's president) ranked first in the estimated value of stock and the amount of increase.

Kang Jung-Suk(Dong-A' Pharm's vice-president) is at the top in the increasing rate.

According to the recent Healthkoreanews' research, president Lim' estimated value of stock has been increased from 178 billion won to 256.4 billion won (up 78.4 billion). And Jung Do-Eon(Ilyang's president), whose estimated value of stock has been increased from 67.6 billion won to 119.2 billion won(up 51.6 billion), ranked second.

Kim Dong-Yun(Bukwang's president)'s estimated value of stock amounts to 147.2 billion won, up 24.8 billion compared to the beginning of this year.

Kang Jung-Suk's estimated value of stock has been increased from 5.2 billion won to 21.6 billion won (up 16.4 billion).

While the KOSPI has showed under 10 % increase for the same period, the estimated value of stock of the above-mentioned 7 persons has been increased by an average of more than 90 %. <헬스코리아뉴스>